Menu Close

New York State Common Retirement Fund Has $17.84 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

view original post

New York State Common Retirement Fund raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 2.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 62,838 shares of the medical research company’s stock after acquiring an additional 1,573 shares during the quarter. New York State Common Retirement Fund owned approximately 0.12% of Charles River Laboratories International worth $17,844,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CRL. Norges Bank bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at $191,481,000. Marshall Wace LLP lifted its holdings in shares of Charles River Laboratories International by 50.3% during the fourth quarter. Marshall Wace LLP now owns 454,795 shares of the medical research company’s stock valued at $171,358,000 after acquiring an additional 152,258 shares during the period. William Blair Investment Management LLC lifted its holdings in shares of Charles River Laboratories International by 14.2% during the fourth quarter. William Blair Investment Management LLC now owns 1,076,250 shares of the medical research company’s stock valued at $405,509,000 after acquiring an additional 133,654 shares during the period. Riverbridge Partners LLC lifted its holdings in shares of Charles River Laboratories International by 51.6% during the first quarter. Riverbridge Partners LLC now owns 259,021 shares of the medical research company’s stock valued at $73,554,000 after acquiring an additional 88,183 shares during the period. Finally, State Street Corp lifted its holdings in shares of Charles River Laboratories International by 3.7% during the fourth quarter. State Street Corp now owns 2,030,795 shares of the medical research company’s stock valued at $765,163,000 after acquiring an additional 73,315 shares during the period. 93.06% of the stock is owned by institutional investors.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $227.64 on Friday. The stock has a 50-day moving average price of $226.50 and a 200 day moving average price of $262.75. The company has a quick ratio of 1.12, a current ratio of 1.33 and a debt-to-equity ratio of 1.13. The firm has a market cap of $11.57 billion, a price-to-earnings ratio of 26.41, a PEG ratio of 1.47 and a beta of 1.29. Charles River Laboratories International, Inc. has a 12 month low of $203.37 and a 12 month high of $460.21.

Charles River Laboratories International (NYSE:CRLGet Rating) last posted its earnings results on Wednesday, August 3rd. The medical research company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.74 by $0.03. The company had revenue of $973.13 million during the quarter, compared to analyst estimates of $995.12 million. Charles River Laboratories International had a return on equity of 21.51% and a net margin of 12.02%. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.61 EPS. Research analysts expect that Charles River Laboratories International, Inc. will post 10.75 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In other news, Director George Massaro sold 178 shares of the business’s stock in a transaction dated Monday, May 9th. The stock was sold at an average price of $230.96, for a total transaction of $41,110.88. Following the completion of the transaction, the director now directly owns 4,677 shares in the company, valued at approximately $1,080,199.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the subject of a number of analyst reports. Guggenheim began coverage on Charles River Laboratories International in a report on Monday, May 23rd. They set a “neutral” rating for the company. They noted that the move was a valuation call. Wells Fargo & Company cut their price target on Charles River Laboratories International from $390.00 to $325.00 and set an “overweight” rating for the company in a report on Monday, April 25th. Morgan Stanley cut Charles River Laboratories International from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $350.00 to $250.00 in a report on Thursday. Stephens set a $315.00 price target on Charles River Laboratories International in a report on Monday, June 20th. Finally, Jefferies Financial Group cut Charles River Laboratories International from a “buy” rating to a “hold” rating and cut their price target for the company from $370.00 to $280.00 in a report on Monday, April 25th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average target price of $361.00.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Articles

Receive News & Ratings for Charles River Laboratories International Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Charles River Laboratories International and related companies with MarketBeat.com’s FREE daily email newsletter.